^
Association details:
| Biomarker: | FGFR2-NRAP fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Lytgobi (futibatinib) (FGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma
Excerpt:
...a 46-year-old male with chronic hepatitis B and recurrent metastatic FGFR2-NRAP fusion-positive ICC involving his liver...On TAS-120, this patient achieved a maximum response of −48%, although this benefit could not be correlated with the ability of the drug to overcome specific resistance mechanisms.
DOI:
https://dx.doi.org/10.1158%2F2159-8290.CD-19-0182
